• Alias: AMG 162; Prolia (osteoporosis trade name)
    • A novel, fully human, highly specific, mAb against the RANKL. The protein is produced in genetically engineered mammalian (Chinese hamster ovary) cells.
    • Blocks osteoclast activation, thereby resulting in reduced bone resorption (less bone breakdown)
    • FDA approved for postmenopausal women with a risk of osteoporosis (Prolia) and for the prevention of skeletal-related events in patients with bone metastases from solid tumors (Xgeva)
    • Recommended dose: 120 mg Sub Q every 4 weeks. Calcium and vitamin D need to be administered in conjunction to avoid hypocalcemia.
    Other topics in Targeted and Immunotherapy Agents